ClinicalTrials.gg
CompletedNCT04840849PK/ADAUpdated Nov 2, 2023Results posted

Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults

A Phase 1 interventional study of nirsevimab and Placebo in Evaluate PK Profile, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-02.

Sponsored by AstraZeneca · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the Pharmacokinetics, Safety, Tolerability of Nirsevimab in Healthy Chinese Adults.

Read the detailed description

This is a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the PK, safety and tolerability, and ADA of nirsevimab when administered as a single fixed IM dosage to healthy Chinese adult subjects. Enrolment is planned at a single study center in China. Approximately 24 subjects will be randomly assigned in a 3:1 ratio to receive nirsevimab (n = 18) or placebo (n = 6). All subjects will be followed for approximately 150 days after dosing to assess safety, PK, and ADA response.

02

Conditions studied

  • Evaluate PK Profile

Keywords

  • PK
  • safety
  • tolerability
  • Nirsevimab
  • healthy Chinese Adults
  • Respiratory Syncytial Viral (RSV)
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 45 years
  2. Weight ≥ 45 kg and ≤ 110 kg and of 19 to 26 kg/m2
  3. Healthy Chinese subjects (both male and female)
  4. Normotensive
  5. Normal (ECG) within 28 days prior to Day 1

Exclusion criteria

Exclusion Criteria:

  1. Acute illness at study entry (pre-dose on Day 1)
  2. Fever ≥99.5°F (37.5°C) on day of dosing
  3. Any drug therapy within 14 days prior to Day 1 (except ).
  4. Receipt of immunoglobulin or blood products within 6 months prior to study entry.
  5. Receipt of any drug therapy within 120 days prior to investigational product dosing or planned to receive any investigational drug therapy within 150 days after investigational product dosing.
  6. Previous receipt of any marketed or investigational mAb.
  7. Previous vaccination against RSV.
  8. History of immunodeficiency or receipt of medications during the prior year.
  9. History of asthma.
  10. History of disorder.
  11. Evidence of any systemic disease on physical examination.
  12. Evidence of infection with hepatitis A, B, or C virus, syphilis, or .
  13. Any abnormal laboratory assessments at screening.
  14. Pregnant or nursing mother.
  15. Alcohol or drug abuse
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Nirsevimab

    Nirsevimab single dose IM injection

    Biological: nirsevimab

  • Placebo comparator
    Placebo

    Placebo single dose IM injection

    Other: Placebo

Interventions

  • Biologicalnirsevimab

    Drug: injection, a single fixed IM dose on day 1 only.

    Also known as: MEDI8897

  • OtherPlacebo

    Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.

06

What researchers measure

Primary outcomes

  1. Serum Concentrations of Nirsevimab

    Serum samples were collected at indicated timepoints to determine the serum concentration of nirsevimab.

    Time frame: Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose.

  2. Maximum Observed Serum Concentration (Cmax) for Nirsevimab

    Cmax for nirsevimab was directly calculated from the individual concentration-time curve.

    Time frame: Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose

  3. Time to Reach Maximum Observed Serum Concentration (Tmax) for Nirsevimab

    Tmax for nirsevimab was directly calculated from the individual concentration-time curve.

    Time frame: Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose

  4. Area Under the Serum Concentration-Time Curve From Time 0 to 150 Days (AUC0-150) for Nirsevimab

    Area Under the Serum Concentration-Time Curve From Time 0 to 150 Days (AUC0-150) for Nirsevimab was calculated by linear up/log down trapezoidal summation.

    Time frame: Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose

Secondary outcomes

  1. Number of Participants With Positive Anti-Drug Antibody (ADA) of Nirsevimab

    ADA positive was defined as any participant with a positive ADA result available at any time, including baseline and all post-baseline measurements; otherwise ADA negative.

    Time frame: Baseline (Day 1) and Days 31, 91 and 151

07

Results

Posted Nov 2, 2023

Participant flow

This was a Phase 1, placebo-controlled, study to evaluate pharmacokinetics (PK), safety, and tolerability of nirsevimab compared to placebo in healthy participants conducted at a single center in China.

Participant flow — Overall Study
MilestoneNirsevimabPlacebo
Started186
Completed186
Not completed00

Outcome measures

PrimarySerum Concentrations of Nirsevimab

Serum samples were collected at indicated timepoints to determine the serum concentration of nirsevimab.

Time frame:
Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose.
Reported as:
Mean · micrograms/milliliter (mcg/mL)
Serum Concentrations of Nirsevimab
micrograms/milliliter (mcg/mL)Nirsevimab
Pre-dose Day 1NA ± NA
Day 227.644 ± 5.819
Day 441.794 ± 8.447
Day 643.811 ± 8.291
Day 846.050 ± 12.484
Day 1543.739 ± 7.236
Day 3140.300 ± 5.391
Day 9125.200 ± 3.694
Day 15117.597 ± 3.854
PrimaryMaximum Observed Serum Concentration (Cmax) for Nirsevimab

Cmax for nirsevimab was directly calculated from the individual concentration-time curve.

Time frame:
Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose
Reported as:
Geometric mean · mcg/mL
Maximum Observed Serum Concentration (Cmax) for Nirsevimab
mcg/mLNirsevimab
Maximum Observed Serum Concentration (Cmax) for Nirsevimab46.882 ± 21.7
PrimaryTime to Reach Maximum Observed Serum Concentration (Tmax) for Nirsevimab

Tmax for nirsevimab was directly calculated from the individual concentration-time curve.

Time frame:
Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose
Reported as:
Median · days
Time to Reach Maximum Observed Serum Concentration (Tmax) for Nirsevimab
daysNirsevimab
Time to Reach Maximum Observed Serum Concentration (Tmax) for Nirsevimab6.99 (4.91 to 29.90)
PrimaryArea Under the Serum Concentration-Time Curve From Time 0 to 150 Days (AUC0-150) for Nirsevimab

Area Under the Serum Concentration-Time Curve From Time 0 to 150 Days (AUC0-150) for Nirsevimab was calculated by linear up/log down trapezoidal summation.

Time frame:
Pre-dose on Day 1 and on Days 2, 4, 6, 8, 15, 31, 91, 151 post-dose
Reported as:
Geometric mean · mcg*day/mL
Area Under the Serum Concentration-Time Curve From Time 0 to 150 Days (AUC0-150) for Nirsevimab
mcg*day/mLNirsevimab
Area Under the Serum Concentration-Time Curve From Time 0 to 150 Days (AUC0-150) for Nirsevimab4210.56 ± 13.6
SecondaryNumber of Participants With Positive Anti-Drug Antibody (ADA) of Nirsevimab

ADA positive was defined as any participant with a positive ADA result available at any time, including baseline and all post-baseline measurements; otherwise ADA negative.

Time frame:
Baseline (Day 1) and Days 31, 91 and 151
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Drug Antibody (ADA) of Nirsevimab
ParticipantsNirsevimab
Baseline (Day 1)0
Day 310
Day 910
Day 1510

Adverse events

Collected over Treatment emergent adverse events were collected from first date of study treatment administration (Day 1) up to 151 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nirsevimab0/18 (0%)0/18 (0%)5/18 (27.8%)
Placebo0/6 (0%)0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
EventNirsevimabPlacebo
Haemoglobin decreasedInvestigations1/181/6
Blood bilirubin increasedInvestigations0/181/6
Urobilinogen urine increasedInvestigations2/180/6
Blood creatinine increasedInvestigations1/180/6
Complement factor decreasedInvestigations1/180/6
Platelet count decreasedInvestigations1/180/6
DiarrhoeaGastrointestinal disorders1/180/6

Baseline characteristics

As-treated population included all participants who were randomized into the study and received any amount of study treatment.

Age, Continuous
Age, Continuous(years)NirsevimabPlaceboTotal
Mean29.2 ± 5.5529.8 ± 4.7129.3 ± 5.26
Sex: Female, Male
Sex: Female, Male(Participants)NirsevimabPlaceboTotal
Female347
Male15217
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)NirsevimabPlaceboTotal
Hispanic or Latino000
Not Hispanic or Latino18624
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)NirsevimabPlaceboTotal
Asian18624
08

Study locations

1 site
  • Research Site
    Shanghai, 200040, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Nov 2021, 4 months.

Results were first posted in Nov 2023, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2021
First posted
Apr 12, 2021
StartActual
Jun 22, 2021
Primary completionActual
Nov 18, 2021
CompletionActual
Nov 18, 2021
Results first posted
Nov 2, 2023
Last update
Nov 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04840849
Lead sponsor
AstraZeneca
Collaborators
IQVIA RDS (Shanghai) Co., Ltd.
Responsible party
Sponsor
First posted
Apr 12, 2021
Start date
Jun 22, 2021
Primary completion
Nov 18, 2021
Completion
Nov 18, 2021
Results posted
Nov 2, 2023
Last update
Nov 2, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirsevimab

Start the discussion